期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ⅡA分泌型磷脂酶A_2与动脉粥样硬化的相关性研究 被引量：2

Relationship between Secretory Phospholipase A_2 of Group ⅡA and Atherosclerosis
在线阅读 下载PDF
导出
摘要 ⅡA分泌型磷脂酶A2(sPLA2-ⅡA)是磷脂酶超家族中的一员,主要是通过介导炎性反应,产生大量脂类介质参与动脉粥样硬化(AS)的发生发展过程,其表达受白细胞介素1β、肿瘤坏死因子α等炎性因子的调节。sPLA2-ⅡA可能是通过有丝分裂原激活蛋白激酶等相关信号通路导致AS的发生。在血管平滑肌细胞表面存在sPLA2-ⅡA致AS作用的受体,阻断这些受体后,致AS的炎性因子表达减少。这些研究可能为AS诊疗提供新的思路。 Secretory phospholipase A2 of group ⅡA（sPLA2-ⅡA） which play an important role in inflammation is one of the the superfamily of phospholipase.In recent years,amount of researches have indicated that sPLA2-ⅡA participated in the formation of atherosclerosis（AS） by mediating the inflammation.The expression of sPLA2-ⅡA is regulated by several cytokines,such as Interleukin-1-β and tumor necrosis factor-α.The sPLA2-ⅡA may associate with AS by the signal pathway of mitogen-activated protion kinase.With further research,some receptors which play an important role in AS were found on the surface of vascular smooth muscle cells,by blocking those receptors,the inflammatory cytokines reduce.These studies may provide new ideas AS treatment.
作者 王玲香 李卫华
机构地区 福建医科大学附属厦门第一医院心血管内科
出处 《医学综述》 2010年第4期496-498,共3页 Medical Recapitulate
基金 厦门市重大疾病攻关项目(A00090 B00010)
关键词 动脉粥样硬化 ⅡA分泌型磷脂酶A2 信号通路 Atherosclerosis Secretory phospholipase A2 of group ⅡA Signal pathway
分类号 R543 [医药卫生—心血管疾病]
  • 相关文献

参考文献20

  • 1Ross R. Atherosclerosis-an inflammatory disease [ J ]. N Engl J Med,1999,340 (2) :115-126.
  • 2Schiering A, Menschikowski M, Mueller E,et al. Analysis of secretory group Ⅱ phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis [ J ]. Atherosclerosis, 1999,144( 1 ) :73-78.
  • 3Hiroshi K,Takuya N,Makoto M,et al. Search of factors that intermediate eytokine-indueedgroup ⅡA phospholipase A expression through the cytosolic phospholipaseAz and 12/15-Lipoxygenase-dependent pathway[J]. J Biol Chem,2005,280(27 ) :25830-25939.
  • 4周秀萍,高应东综述,彭怀燕审校.ⅡA分泌型磷脂酶A_2与心血管疾病[J].中国动脉硬化杂志,2005,13(2):239-241. 被引量：6
  • 5Li WH,Sun C,Xie Q,et al. Simvastatin inhibits sPLA2ⅡA expression in aorta and myoeardium[J]. Arch Med Res,2009,40(2):62-67.
  • 6Holvoet P, Mertens A, Verhamme P,et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease[J]. Arterioscler Thromb Vasc Biol,2001,21 (5) :844-848.
  • 7Elinder LS, Dumitrescu A, Larsson P, et al. Expression of phospholipase A2 isoforms in human normal and atheroselerotie arterial wall [J]. Arterioscler Thromb Vasc Biol, 1997,17(10) :2257-2263.
  • 8Kugiyama K, Ota Y, Kawano H, et al. Increase in plasma levels of secretory type Ⅱ phospholi-pase A2 in patients with coronary spastic angina[ J]. Cardiovase Res,2000,47 ( 1 ) : 159-165.
  • 9Morimoto M, Kume N, Miyamoto S, et al. Lysophosphatidylcholine induces early growth response factor-1 expression and activates the core promoter of PDGF-A chain in vascular endothelial cells [ J ]. Arterioseler Thromb Vase Biol,2001,21 (5) :771-776.
  • 10Webb NR, Bostrom MA, Szilvassy SJ, et al. Macrophage-expressed group ⅡA secretory phospholipase A2 increases atheroscleretic lesion formation in LDL receptor-deficient mice [ J ]. Arterioscler Thromb Vasc Biol, 2003,23 ( 3 ) : 263 -268.

二级参考文献30

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：348
  • 2Ross R. Atherosclerosis an inflammatory disease. N Engl J Med, 1999, 340(2):115-126.
  • 3Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta, 2000, 1 488 (1-2):1-19.
  • 4Morimoto M, Kume N, Muyamoto S, Ueno Y, Kataoka H, Minami M, et al.Lysophosphatidylcholine induces early growth response factor-1 expression and activates the core promoter of PDGF-A chain in vascluar endothelial cells. Arterioscler Thromb, 2001, 21(5): 771-776.
  • 5Gelb MH, Valentin E, Ghomashchi F, Lazdunski M, Lambeau G. Cloning and recombinant expression of a structurally novel human secreted phospholipase A2. J Biol Chem, 2000,275(51): 39 823-826.
  • 6Ishizaki J, Suzuki N, Higashino K, Yokota Y, Ono T, Kawamoto K, et al.. Cloning and characterization of novel mouse and human secretory phospholipase A2. J Biol Chem, 1999, 274(35): 24 973-979.
  • 7Romano M, Romano E, Bjorkerud S, Hurt-Camejo E. Ultrastructural localization of secretory type Ⅱphospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Biol, 1998, 18(4):519-525.
  • 8Hurt-Camejo E, Anderssen S, Standal R, Rosengren B, Sartipy P, Stadberg E, et al. Localization of non pancreatic secretory phospholipase A2in normal and atherosclerotic arteries: activity of the isolated enzyme on low density lipoprotein. Arterioscler Thromb Vasc Biol, 1997,17 (2): 300-309.
  • 9Menschikowski M, Rosner-Schiering A, Eckey R, Mueller E, Koch R,Jaross W. Expression of secretory group ⅡA phospholipase A2 in relationto the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. Arterioscler Thromb Vasce Biol, 2000, 20(3): 751-762.
  • 10Kugiyama K, Ota Y, Kawano H, Soejima H, Ogawa H, Sugiyama S, et al. Increase in plasma levels of secretory type Ⅱ phospholipase A2 in patients with coronary spastic angina. Cardiovasc Res, 2000,47 (1): 159-165.

共引文献9

同被引文献36

  • 1陈隽妍,毛威,倪桂宝,李剑钢.动脉粥样硬化痰瘀互结证大鼠模型的建立[J].现代中西医结合杂志,2007,16(26):3789-3793. 被引量：9
  • 2黄继汉,黄晓晖,陈志扬,郑青山,孙瑞元.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学,2004,9(9):1069-1072. 被引量：1423
  • 3徐丹,杨关林.从痰瘀方面浅谈冠心病病因病机[J].中外健康文摘,2009,6(25):256-257.
  • 4Vittos O, Toana B, Vittos A, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) : a review of its role and significance as a cardiovascular bi- omarker[J ]. Biomarkers, 2012, 17(4) : 289 -302.
  • 5Ait-Oufella H, Mallat Z, Tedgui A. Lp-PLA2 and sPLA2 : cardiovascular biomarkers [ J ]. Med Sci, 2014, 30(5) : 526 -531.
  • 6Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) bound to LDL and HDL[J]. Curr Pharm Des, 2014,20(40)- 6256 - 6269.
  • 7Caviqiolio G, Jayaraman S. Proteolysis of apolipoprotein A-I by secretory phospholipase A2: a new link between inflammation and atherosclerosis [ J ]. J Biol Chem, 2014, 289(14): 10011 -10023.
  • 8Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. Lipoprotein-associated phospho- lipase A (2) and risk of coronary disease, stroke, and mortality, collaborative analysis of 32 prospective studies [ J ]. Lancet, 2010, 375 (9725) : 1536 -1544.
  • 9Hatoum I J, Cook NR, Nelson J J, et al. Lipopro- tein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women[J]. Am Heart J, 2011, 161(3): 516-522.
  • 10Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis [ J ]. Nat Rev Drug Discov, 2011, 10(5) : 365 -376.

引证文献2

二级引证文献32

医学综述
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部